A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer has failed in a late stage trial, the Swiss pharmaceuticals maker said on Wednesday. Interim results from the phase III Skyscraper-01 study did not meet the target of progressionfree survival in patients with high metastatic non-small cell lung cancer, it said. The other primary endpoint of overall survival was found to be "immature" or incomplete, Roche said, adding the study will continue.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!